M. Mauri

发表

Anthropometric, clinical and molecular determinants of treatment outcomes in postmenopausal, hormone receptor positive metastatic breast cancer patients treated with fulvestrant: Results from a real word setting

L. Moscetti, I. Sperduti, P. Vici, 2017, Oncotarget.

Fulvestrant 500 milligrams as endocrine therapy for endocrine sensitive advanced breast cancer patients in the real world: the Ful500 prospective observational trial.

A. Grassadonia, L. Moscetti, I. Sperduti, 2017, Oncotarget.

Anthropometric, clinical and molecular determinants of treatment outcomes in postmenopausal, hormone receptor positive metastatic breast cancer patients treated with fulvestrant: Results from a real word setting

L. Moscetti, I. Sperduti, P. Vici, 2017, OncoTarget.

Is delayed chemotherapy-induced emesis well managed in oncological clinical practice?

G. Tonini, F. Cognetti, A. Fabi, 2003, Supportive Care in Cancer.

Identification of subgroups of early breast cancer patients at high risk of nonadherence to adjuvant hormone therapy: results of an Italian survey.

N. Tinari, E. Cianchetti, A. Grassadonia, 2015, Clinical breast cancer.

Bevacizumab as First-Line Treatment in HER2-Negative Advanced Breast Cancer: Pros and Cons

P. Marchetti, G. Tonini, M. De Laurentiis, 2016, Tumori.

Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti‐HER2 agents in the real world setting

S. Barni, N. Tinari, G. Ciliberto, 2019, International journal of cancer.

Safety analysis, association with response and previous treatments of everolimus and exemestane in 181 metastatic breast cancer patients: A multicenter Italian experience.

P. Marchetti, L. Moscetti, D. Santini, 2016, Breast.